Method
What did CBDV trials test?
Among the varin cannabinoids, CBDV has the most public human-trial history, which is not the same as a positive result. CBG Atlas records a completed randomised controlled trial of CBDV whose primary endpoint was not met. Peregrine reports that outcome as it stands rather than reframing secondary findings as a benefit, and sells CBDV isolate (CAS 24274-48-4) as an ingredient.
Origin
Details and citations are in the CBG Atlas CBDV monograph. Peregrine sells CBDV isolate and does not describe a missed primary endpoint as ‘promising’.
Established
- CBDV is the propyl homolog of CBD (CAS 24274-48-4).
- Human trials of CBDV exist; at least one completed RCT missed its primary (Atlas).
Not yet
- A Peregrine efficacy claim for CBDV.
- Any reading of ‘the largest varin human file’ as evidence that it works.
Questions
If the primary missed, why sell CBDV?
Because formulators and analytical labs specify the molecule for their own reasons. We sell the isolate; we do not sell a result.
Evidence language follows CBG Atlas (Peregrine-funded; editorial independence). Not medical advice. Not a disease claim.
Related
Educational, not medical advice. Nothing here diagnoses, treats, cures or prevents any disease. Wholesale isolates are ingredients, not finished supplements. Education is aligned with CBG Atlas, which Peregrine funds without editorial control.